BioNTech SE is a German biotechnology company that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. The company's product portfolio includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies, and small molecules. BioNTech's clinical pipeline includes treatments for cancer, infectious diseases, and rare diseases. The company was founded in 2008 and is headquartered in Mainz, Germany.